WO2006011154A1 - A novel polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) and a process for producing thereof - Google Patents

A novel polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) and a process for producing thereof Download PDF

Info

Publication number
WO2006011154A1
WO2006011154A1 PCT/IN2004/000227 IN2004000227W WO2006011154A1 WO 2006011154 A1 WO2006011154 A1 WO 2006011154A1 IN 2004000227 W IN2004000227 W IN 2004000227W WO 2006011154 A1 WO2006011154 A1 WO 2006011154A1
Authority
WO
WIPO (PCT)
Prior art keywords
donepezil
hydrochloride
amorphous
polymorph
donepezil hydrochloride
Prior art date
Application number
PCT/IN2004/000227
Other languages
French (fr)
Inventor
Venkatasubramanian Radhakrishnan Tarur
Dhananjay Govind Sathe
Avinash Venkataraman Naidu
Umesh Parashram Aher
Kamlesh Digambar Sawant
Original Assignee
Usv Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Usv Limited filed Critical Usv Limited
Priority to PCT/IN2004/000227 priority Critical patent/WO2006011154A1/en
Priority to EP04806738A priority patent/EP1771416A1/en
Priority to US11/145,202 priority patent/US7186842B2/en
Publication of WO2006011154A1 publication Critical patent/WO2006011154A1/en
Priority to US11/412,294 priority patent/US20080076928A1/en
Priority to US11/557,764 priority patent/US20070123565A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to a novel, stable polymorph of l-benzyl-4-[(5,6- dimethoxy-l-indanone)-2-yl] methyl piperidine hydrochloride commonly known as Donepezil hydrochloride. Further the present invention relates to a process for producing Donepezil HCl amorphous and it's polymorph Form (VI).
  • Donepezil hydrochloride (I) has excellent action as a prophylactic and a therapeutic agent for senile dementia, and in particular as a prophylactic and therapeutic agent for Alzheimer's disease and an industrial process for producing the same, has been reported.
  • the process for the preparation of l-benzyl-4-[(5,6-dimethoxy-l-indanone)-2-yl] methyl piperidine has been described in JP A-64-79151 (US-4895841, EP 296560).
  • Japanese patent application, publication No. A-100-53576 discloses certain forms (I, II, III, IV & V) of Donepezil hydrochloride, l-benzyl-4-[(5,6- dimethoxy-l-indanone)-2-yl] methyl piperidine hydrochloride.
  • This patent also discloses an amorphous form of Donepezil hydrochloride, which is reported to be chemically unstable on storage.
  • the present invention describes a novel, stable polymorph form (VI) of l-benzyl-4- [(5,6-dimethoxy-l-indanone)-2-yl] methyl piperidine, hydrochloride.
  • the said polymorph form (VI) is characterized by powder X-ray diffraction patterns shown in Fig 1. Further the said polymorph is characterized by IR recorded in KBr as shown in Fig 2.
  • the present invention describes a process for making Donepezil hydrochloride amorphous from Donepezil oxalate wherein the said process comprises dissolving the said Donepezil oxalate in water in the temperature range of 40 to 60° C, preferably 50° C; basifying the solution of said Donepezil oxalate with base to convert it into Donepezil base; extracting the said Donepezil base in a solvent; acidifying the said Donepezil base with inorganic acid, preferably hydrochloric acid to obtain the said Donepezil HCl and spray drying the said Donepezil HCl solution in water to obtain Donepezil HCl amorphous form.
  • the present invention describes a process for making Donepezil hydrochloride polymorph form (VI) from Donepezil hydrochloride amorphous at room temperature at relative humidity.
  • a pharmaceutical composition comprising a therapeutically effective amount of the said Donepezil HCl amorphous or its polymorph form (VI) is also envisaged as part of this invention.
  • a method of treating senile dementia of Alzheimer's disease comprising administering to a warm blooded animal an effective amount of a product-by-process composition of matter comprising the said Donepezil HCl amorphous or it's polymorphic form (VI) is also envisaged as part of this invention.
  • compound (I) as a novel polymorphic form of hydrochloride salt.
  • the novel salt can be prepared by an efficient, economic and reproducible process and is particularly suited to large-scale preparation.
  • the hydrochloride salt is therefore surprisingly amenable to large scale pharmaceutical processing and formulation.
  • the present invention specifically relates to the novel polymorphic form of Donepezil hydrochloride, which is characterized by powder X-ray diffraction and / or infrared absorption peaks recorded in potassium bromide.
  • the novel polymorphic form of compound (I) is hereafter referred as Donepezil hydrochloride form (VI).
  • the Donepezil hydrochloride form (VI) has specific melting characteristics. It melts in the range of 70 to 90° C, resolidifies in the range of 130 to 150° C and remelts in the range of 210 to 230° C.
  • the present invention encompasses the Donepezil hydrochloride form (VI) isolated in a purified form. Also, the invention provides Donepezil hydrochloride form (VI) in a pharmaceutically acceptable form, especially in bulk form, such form having good flow properties, especially good bulk flow properties.
  • the present invention uses Donepezil oxalate (reported in our earlier US CIP application serial number dated 29 l June 2004 herein incorporated as reference) which is prepared by treating l-benzyl-4-[(5,6-dimethoxy-l-indanone)-2- yl]methyl piperidine compound (I) (Process for the Compound I is reported in our patent US6649765, herein incorporated as reference) with oxalic acid in suitable solvent.
  • the concentration of compound (I) is preferably in the range of from 3 to 25 % weight/volume, more preferably in the range of from 5 to 20 %.
  • the concentration of oxalic acid solution is preferably in the range of from 3 to 50% weight/volume.
  • the reaction is usually carried out at ambient temperature or at an elevated temperature, although any convenient temperature that provides the required product may be employed.
  • the temperature is in the range of 20-120 0 C, preferably 40 0 C to 90° C, more preferably 70° C.
  • the suitable solvent is an alkanol, for example propan-2-ol, or a ketone, such as acetone, an ester, such as ethyl acetate.
  • the invention provides a novel process for the preparation of the Donepezil hydrochloride amorphous form, which comprises the following steps:
  • Donepezil oxalate is dissolved in water and basified.
  • Donepezil base thus obtained, is extracted in a suitable solvent and acidified with aqueous hydrochloric acid.
  • the solvent is evaporated and aqueous acidic solution of Donepezil hydrochloride is lyophilized to obtain Donepezil hydrochloride amorphous form.
  • the bases used are inorganic bases such as ammonia, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, preferably ammonia.
  • a suitable solvent is an organic solvent, such as toluene, ethyl acetate, a halogenated hydrocarbon such as dichloromethane, chloroform, preferably dichloromethane.
  • the concentration of Donepezil oxalate solution in water is preferably in the range of from 5 to 25 % weight/volume, more preferably in the range of from 5 to 15 %.
  • the dissolution of Donepezil oxalate in water is usually carried out at ambient temperature or at an elevated temperature, although any convenient temperature that provides the required product may be employed.
  • the temperature is in the range of 20- 80 0 C, preferably 25 0 C to 50° C 5 more preferably 35° C.
  • Lyophilization is usually carried out in the temperature range of -20 to -80 C, preferably 5 0 C to -50° C, more preferably -35° C.
  • the invention also provides a process for preparing Donepezil hydrochloride amorphous by spray drying Donepezil hydrochloride in water.
  • Spray drying is carried out in the temperature range of 80 -120° C, preferably 90 to 110° C, more preferably 100° C.
  • the invention also provides a process for the preparation of the Donepezil hydrochloride form (VI), in which Donepezil hydrochloride amorphous is obtained by lyophilization or spray drying and kept at room temperature under humid atmosphere.
  • the room temperature is in the range of 25 to 35° C, preferably 29 to 31° C.
  • the relative humidity is in the range of 60 to 80%, preferably 65 to 75%.
  • Donepezil base is prepared by a process as described in US 6,649,765 Bl and is incorporated here as a reference. There after the base is converted to the novel form (VI) of Donepezil hydrochloride as mentioned below:
  • Donepezil oxalate obtained by treatment of ethyl acetate solution of Donepezil free base with a solution of oxalic acid in acetone is filtered and dried.
  • Donepezil oxalate is further purified in an organic solvent such as methanol.
  • Donepezil oxalate is dissolved in water and basified with a base, such as sodium hydroxide to liberate Donepezil free base.
  • Donepezil hydrochloride 7.
  • the aqueous solution of Donepezil hydrochloride is lyophilized to form Donepezil hydrochloride amorphous.
  • Donepezil hydrochloride 8. The aqueous solution of Donepezil hydrochloride is spray dried to form Donepezil hydrochloride amorphous.
  • Peaks in the powder x-ray diffraction pattern are:
  • Wave numbers (cm "1 ) of infrared absorption spectra recorded in potassium bromide are: 443.6, 451.3, 464.8, 498.6, 518.8, 534.2, 549.3, 59.3, 605.6, 630, 651.9, 673, 707.8, 759.9, 785, 806.2, 848.6, 862.1, 891.1, 920, 947, 970.1, 979.8, 1010.6, 1037.6, 1064.6, 1085.9, 1116.7, 1157.2, 1193.9, 1224.7, 1265.2, 1317.3, 1363.6, 1429.2, 1454.2, 1469.7, 1468.6, 1589.2, 1604.7, 1629.7, 1691.5, 1913.3, 1992.3, 2061.8, 2248.8, 2345.3, 2542, 2561.3, 2588.3, 2636.5, 2669.3, 2696.3, 2721.4, 2835.2, 2873.7, 2925.8, 3031.9, 3255.6, 3355.9,
  • Fig. 1 shows a powder X-ray diffraction pattern for Donepezil hydrochloride form (VI)
  • Fig. 2 shows an infrared absorption spectrum for Donepezil hydrochloride form (VI).
  • x-ray diffraction angles x-ray intensities and infrared (“IR") wave values are approximate; the numerical values here disclosed are therefore intended to encompass a range of approximately ⁇ 0.3 about each stated value.
  • IR values ... as follows; 443.6, 451.3, 464.8” is intended to encompass IR values of a range of from 443.3 to 443.9; and a range of from 451.0 to 451.6; and a range of from 464.5 to 465.1.
  • claim terms incorporating parameters illustrated by the Figures do not require exact equality in physical characteristics; a variation of approximately ⁇ 0.3 about each value along the parameters shown in each Figure is to be expected.
  • Donepezil oxalate 5 gms was dissolved in methanol 25 ml under heating at 50° C. Stirring was continued for 1 hour with gradual cooling. Stirring was further continued for 1 hour at room temperature. Filtration of the crystals and drying at 60° C afforded the title compound with a yield of 4.0 gms (80%) and melting point of 177-78° C.
  • Donepezil oxalate (purified, example 2), 5 gms, was dissolved in water 50 ml under heating at 50° C. Stirring was continued for 1 hour with gradual cooling. At room temperature, dichloromethane 50 ml was added and stirred for 10 mins. Liquid Ammonia 5 ml was added slowly with stirring. The dichloromethane layer was separated and 50 ml water was added to it. Analytical grade concentrated hydrochloric acid 1.5 ml was slowly added and stirred for 10 mins.
  • Donepezil hydrochloride in water (prepared as given in example 3), which was spray dried at 100° C, to give Donepezil hydrochloride amorphous with a yield of 3.4 gms (82.9%).
  • Example 5
  • Donepezil hydrochloride amorphous 5 gm was kept at room temperature at relative humidity 70-80% for 24 hours to give the Donepezil hydrochloride form (VI) with a yield of 5.3 gms and melting point 215-218° C. Moisture content (KF 6.4 %).

Abstract

The present invention discloses a novel, stable polymorph of 1-benzyl-4-[(5,6 dimethoxy-l-indanone)-2-y1] methyl piperidine hydrochloride commonly known as Donepezil hydrochloride. Further the present invention discloses a process for producing Donepezil HCl amorphous and it's polymorph Form (VI).

Description

A novel polymorph of (l-benzyI-4-[(5,6-dimethoxy-l-indanone)-2-yl] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof.
Related Applications
This application is related to US Application Serial No. filed June 29
2004.
Cross Reference to Related Applications
This application is continuation-in-part of U.S. Application Serial No. 10/365,717 filed February 12, 2003 and US 6,649,765, which is entirely incorporated herein by reference.
Technical Field
The present invention relates to a novel, stable polymorph of l-benzyl-4-[(5,6- dimethoxy-l-indanone)-2-yl] methyl piperidine hydrochloride commonly known as Donepezil hydrochloride. Further the present invention relates to a process for producing Donepezil HCl amorphous and it's polymorph Form (VI).
Background and Prior art:
Donepezil hydrochloride (I) has excellent action as a prophylactic and a therapeutic agent for senile dementia, and in particular as a prophylactic and therapeutic agent for Alzheimer's disease and an industrial process for producing the same, has been reported. The process for the preparation of l-benzyl-4-[(5,6-dimethoxy-l-indanone)-2-yl] methyl piperidine has been described in JP A-64-79151 (US-4895841, EP 296560).
Figure imgf000003_0001
(I)
Japanese patent application, publication No. A-100-53576 (WO 9746527) discloses certain forms (I, II, III, IV & V) of Donepezil hydrochloride, l-benzyl-4-[(5,6- dimethoxy-l-indanone)-2-yl] methyl piperidine hydrochloride. This patent also discloses an amorphous form of Donepezil hydrochloride, which is reported to be chemically unstable on storage.
US patent 6,734,195 claims a chemically stable amorphous form of Donepezil hydrochloride and its use in formulation.
The US patent 6,734,195 however has not reported any polymorphic stability of amorphous form. However the above JP patent A-100-53576 (WO 9746527) reports conversion of amorphous form to crystalline form (IV) when exposed to more than 90% relative humidity at room temperature.
Summary of the invention
The present invention describes a novel, stable polymorph form (VI) of l-benzyl-4- [(5,6-dimethoxy-l-indanone)-2-yl] methyl piperidine, hydrochloride. The said polymorph form (VI) is characterized by powder X-ray diffraction patterns shown in Fig 1. Further the said polymorph is characterized by IR recorded in KBr as shown in Fig 2.
Further the present invention describes a process for making Donepezil hydrochloride amorphous from Donepezil oxalate wherein the said process comprises dissolving the said Donepezil oxalate in water in the temperature range of 40 to 60° C, preferably 50° C; basifying the solution of said Donepezil oxalate with base to convert it into Donepezil base; extracting the said Donepezil base in a solvent; acidifying the said Donepezil base with inorganic acid, preferably hydrochloric acid to obtain the said Donepezil HCl and spray drying the said Donepezil HCl solution in water to obtain Donepezil HCl amorphous form.
Further the present invention describes a process for making Donepezil hydrochloride polymorph form (VI) from Donepezil hydrochloride amorphous at room temperature at relative humidity.
A pharmaceutical composition comprising a therapeutically effective amount of the said Donepezil HCl amorphous or its polymorph form (VI) is also envisaged as part of this invention.
A method of treating senile dementia of Alzheimer's disease, the method comprising administering to a warm blooded animal an effective amount of a product-by-process composition of matter comprising the said Donepezil HCl amorphous or it's polymorphic form (VI) is also envisaged as part of this invention. Detailed Description
Surprisingly the amorphous form of Donepezil hydrochloride when prepared in our laboratory as reported in the JP A-100-53576 (WO 9746527), was found to undergo changes in the polymorphic form, when the amorphous form was kept at room temperature and a relative humidity of around 70%. This form was quite different than form (IV) reported in JP A-10-53576.
Thus we describe compound (I) as a novel polymorphic form of hydrochloride salt. The novel salt can be prepared by an efficient, economic and reproducible process and is particularly suited to large-scale preparation. The hydrochloride salt is therefore surprisingly amenable to large scale pharmaceutical processing and formulation.
The present invention specifically relates to the novel polymorphic form of Donepezil hydrochloride, which is characterized by powder X-ray diffraction and / or infrared absorption peaks recorded in potassium bromide.
The novel polymorphic form of compound (I) is hereafter referred as Donepezil hydrochloride form (VI).
The Donepezil hydrochloride form (VI) has specific melting characteristics. It melts in the range of 70 to 90° C, resolidifies in the range of 130 to 150° C and remelts in the range of 210 to 230° C.
The present invention encompasses the Donepezil hydrochloride form (VI) isolated in a purified form. Also, the invention provides Donepezil hydrochloride form (VI) in a pharmaceutically acceptable form, especially in bulk form, such form having good flow properties, especially good bulk flow properties.
The present invention uses Donepezil oxalate (reported in our earlier US CIP application serial number dated 29 l June 2004 herein incorporated as reference) which is prepared by treating l-benzyl-4-[(5,6-dimethoxy-l-indanone)-2- yl]methyl piperidine compound (I) (Process for the Compound I is reported in our patent US6649765, herein incorporated as reference) with oxalic acid in suitable solvent.
The concentration of compound (I) is preferably in the range of from 3 to 25 % weight/volume, more preferably in the range of from 5 to 20 %. The concentration of oxalic acid solution is preferably in the range of from 3 to 50% weight/volume.
The reaction is usually carried out at ambient temperature or at an elevated temperature, although any convenient temperature that provides the required product may be employed. The temperature is in the range of 20-1200C, preferably 400C to 90° C, more preferably 70° C.
The suitable solvent is an alkanol, for example propan-2-ol, or a ketone, such as acetone, an ester, such as ethyl acetate.
The invention provides a novel process for the preparation of the Donepezil hydrochloride amorphous form, which comprises the following steps:
Donepezil oxalate is dissolved in water and basified. Donepezil base thus obtained, is extracted in a suitable solvent and acidified with aqueous hydrochloric acid. The solvent is evaporated and aqueous acidic solution of Donepezil hydrochloride is lyophilized to obtain Donepezil hydrochloride amorphous form.
The bases used are inorganic bases such as ammonia, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, preferably ammonia.
A suitable solvent is an organic solvent, such as toluene, ethyl acetate, a halogenated hydrocarbon such as dichloromethane, chloroform, preferably dichloromethane.
The concentration of Donepezil oxalate solution in water is preferably in the range of from 5 to 25 % weight/volume, more preferably in the range of from 5 to 15 %.
The dissolution of Donepezil oxalate in water is usually carried out at ambient temperature or at an elevated temperature, although any convenient temperature that provides the required product may be employed. The temperature is in the range of 20- 800C, preferably 250C to 50° C5 more preferably 35° C.
Lyophilization is usually carried out in the temperature range of -20 to -80 C, preferably 50C to -50° C, more preferably -35° C.
The invention also provides a process for preparing Donepezil hydrochloride amorphous by spray drying Donepezil hydrochloride in water.
Spray drying is carried out in the temperature range of 80 -120° C, preferably 90 to 110° C, more preferably 100° C.
The invention also provides a process for the preparation of the Donepezil hydrochloride form (VI), in which Donepezil hydrochloride amorphous is obtained by lyophilization or spray drying and kept at room temperature under humid atmosphere. The room temperature is in the range of 25 to 35° C, preferably 29 to 31° C.
The relative humidity is in the range of 60 to 80%, preferably 65 to 75%.
X-ray powder diffraction pattern has been obtained on D 8 —Advance, Bruker AXE, Germany, diffractometer equipped with scintillation detector using Copper Ka (λ = 1.5406 A) radiation with scanning range between 2-50 θ (theta)at scanning speed of 2°/min.
Detailed process for preparing the Donepezil hydrochloride form (VI) is given below,
Donepezil base is prepared by a process as described in US 6,649,765 Bl and is incorporated here as a reference. There after the base is converted to the novel form (VI) of Donepezil hydrochloride as mentioned below:
1. Donepezil oxalate, obtained by treatment of ethyl acetate solution of Donepezil free base with a solution of oxalic acid in acetone is filtered and dried.
2. Donepezil oxalate is further purified in an organic solvent such as methanol.
3. Pure Donepezil oxalate is dissolved in water and basified with a base, such as sodium hydroxide to liberate Donepezil free base.
4. The Donepezil free base is extracted in dichloromethane.
5. Dichloromethane layer containing Donepezil free base is stirred with aqueous hydrochloric acid to form Donepezil hydrochloride. 6. Dichloromethane is evaporated to leave an aqueous solution of Donepezil hydrochloride.
7. The aqueous solution of Donepezil hydrochloride is lyophilized to form Donepezil hydrochloride amorphous.
8. The aqueous solution of Donepezil hydrochloride is spray dried to form Donepezil hydrochloride amorphous.
9. The Donepezil hydrochloride amorphous is exposed to humidity to form polymorph (VI).
Donepezil hydrochloride form (VD
Peaks in the powder x-ray diffraction pattern are:
Figure imgf000009_0001
Figure imgf000010_0001
Wave numbers (cm"1) of infrared absorption spectra recorded in potassium bromide are: 443.6, 451.3, 464.8, 498.6, 518.8, 534.2, 549.3, 59.3, 605.6, 630, 651.9, 673, 707.8, 759.9, 785, 806.2, 848.6, 862.1, 891.1, 920, 947, 970.1, 979.8, 1010.6, 1037.6, 1064.6, 1085.9, 1116.7, 1157.2, 1193.9, 1224.7, 1265.2, 1317.3, 1363.6, 1429.2, 1454.2, 1469.7, 1468.6, 1589.2, 1604.7, 1629.7, 1691.5, 1913.3, 1992.3, 2061.8, 2248.8, 2345.3, 2542, 2561.3, 2588.3, 2636.5, 2669.3, 2696.3, 2721.4, 2835.2, 2873.7, 2925.8, 3031.9, 3255.6, 3355.9, 3367.5, 3517.9, 3548.8 Brief description of drawings :
Fig. 1 shows a powder X-ray diffraction pattern for Donepezil hydrochloride form (VI) Fig. 2 shows an infrared absorption spectrum for Donepezil hydrochloride form (VI).
Donepezil hydrochloride form (VI):
Peaks in powder X-ray diffraction pattern (See Fig. 1):
Peaks in infrared absorption spectrum recorded in potassium bromide (See Fig. 2):
The designations of x-ray diffraction angles, x-ray intensities and infrared ("IR") wave values are approximate; the numerical values here disclosed are therefore intended to encompass a range of approximately ± 0.3 about each stated value. Thus, for example, the term "IR values ... as follows; 443.6, 451.3, 464.8" is intended to encompass IR values of a range of from 443.3 to 443.9; and a range of from 451.0 to 451.6; and a range of from 464.5 to 465.1. Similarly, claim terms incorporating parameters illustrated by the Figures do not require exact equality in physical characteristics; a variation of approximately ± 0.3 about each value along the parameters shown in each Figure is to be expected.
Examples
The present invention will now be described in more detail with reference to the following examples. It is needless to say that the technical scope of the present invention is not limited to these examples.
Example 1
To Donepezil base (obtained after benzylation which is reported in our patent US6649765, herein incorporated as reference) (10 gms.) in ethyl acetate (200 ml) was added oxalic acid (5 gms dissolved in 100 ml acetone) slowly with stirring. After addition, the reaction mass was concentrated in vacuum. The solid separated was filtered, washed with acetone and dried at 60° C to afford the title compound with a yield of 12 gms (90.2%) and melting point of 176-77° C.
Example 2
Donepezil oxalate 5 gms was dissolved in methanol 25 ml under heating at 50° C. Stirring was continued for 1 hour with gradual cooling. Stirring was further continued for 1 hour at room temperature. Filtration of the crystals and drying at 60° C afforded the title compound with a yield of 4.0 gms (80%) and melting point of 177-78° C.
Example 3
Donepezil oxalate (purified, example 2), 5 gms, was dissolved in water 50 ml under heating at 50° C. Stirring was continued for 1 hour with gradual cooling. At room temperature, dichloromethane 50 ml was added and stirred for 10 mins. Liquid Ammonia 5 ml was added slowly with stirring. The dichloromethane layer was separated and 50 ml water was added to it. Analytical grade concentrated hydrochloric acid 1.5 ml was slowly added and stirred for 10 mins. Dichloromethane was distilled off under vacuum at 45° C to obtain Donepezil hydrochloride in water, which was kept for lyophilyzation for 24 hours at -350C to give Donepezil hydrochloride amorphous with a yield of 3.9 gms (95%).
Example 4
Donepezil hydrochloride in water (prepared as given in example 3), which was spray dried at 100° C, to give Donepezil hydrochloride amorphous with a yield of 3.4 gms (82.9%). Example 5
Donepezil hydrochloride amorphous 5 gm was kept at room temperature at relative humidity 70-80% for 24 hours to give the Donepezil hydrochloride form (VI) with a yield of 5.3 gms and melting point 215-218° C. Moisture content (KF 6.4 %).

Claims

We Claim
1. A novel, stable polymorph form (VI) of l-benzyl-4-[(5,6-dimethoxy-l-indanone)-2- yl] methyl piperidine, hydrochloride.
2. The polymorph form (VI) as claimed in claim 1, wherein the said polymorph form (VI) is characterized by peaks at the diffraction angles (2Θ) in its powder X-ray diffraction pattern, as given below:
Figure imgf000014_0001
3. The polymorph form (VI) as claimed in claim 1, wherein the said polymorph is characterized by peaks at wave numbers in cm"1 in IR recorded in KBr as given below:
651.9, 707.8, 759.9, 806.2, 848.6, 862.1, 947, 970.1, 979.8, 1037.6, 1116.7, 1224.7,
1265.2, 1317.3, 1363.6, 1454.2, 1469.7, 1468.6, 1589.2, 1604.7, 1629.7, 1691.5,
2561.3, 2588.3, 2636.5, 2669.
3, 2721.4, 2835.2, 2873.7, 2925.8, 3255.6, 3355.9, 3367.5, 3517.9, 3548.8
4. A process for making Donepezil hydrochloride amorphous from Donepezil oxalate comprising dissolving the said Donepezil oxalate in water in the temperature range of 40 to 60° C, preferably 50° C; basifying the solution of said Donepezil oxalate with base to convert it into Donepezil base; extracting the said Donepezil base in a solvent; acidifying the said Donepezil base with inorganic acid, preferably hydrochloric acid to obtain the said Donepezil HCl and spray drying the said Donepezil HCl solution in water to obtain Donepezil HCl amorphous form.
5. The process as claimed in claim 4 wherein the said base used may be selected from ammonia, sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, preferably ammonia.
6. The process as claimed in claim 4 wherein the said solvent may be selected from a hydrocarbon, preferably toluene, a ester, preferably ethyl acetate, and a halogenated hydrocarbon, preferably dichloromethane, chloroform, more preferably dichloromethane .
7. The process as claimed in claim 4 to 6 wherein the said Donepezil hydrochloride in water is spray dried in the temperature range of 80 to 120° C, preferably 90 to 110° C, more preferably 100° C.
8. A process for making Donepezil hydrochloride polymorph form (VI) from Donepezil hydrochloride amorphous at room temperature at relative humidity.
9. The process as claimed in claim 8 wherein the said room temperature range to prepare the said polymorph is 25 to 35° C, preferably 29 to 31° C.
10. The process as claimed in claim 8 wherein the said relative humidity to prepare the said polymorph is 60 to 80%, preferably 65 to 75%.
11. A pharmaceutical composition comprising a therapeutically effective amount of the said Donepezil HCl amorphous or its polymorph form (VI) as prepared by the process claimed in any of the above claims.
12. A method of treating senile dementia of Alzheimer's disease, the method comprising administering to a warm blooded animal an effective amount of a product-by-process composition of matter comprising the said Donepezil HCl amorphous or it's polymorphic form (VI) wherein the said Donepezil HCl amorphous polymorphic form (VI) manufactured by the process as claimed in any of the claims 1 to 10.
PCT/IN2004/000227 2003-02-12 2004-07-28 A novel polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) and a process for producing thereof WO2006011154A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PCT/IN2004/000227 WO2006011154A1 (en) 2004-07-28 2004-07-28 A novel polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) and a process for producing thereof
EP04806738A EP1771416A1 (en) 2004-07-28 2004-07-28 A novel polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) and a process for producing thereof
US11/145,202 US7186842B2 (en) 2003-02-12 2005-06-03 Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof
US11/412,294 US20080076928A1 (en) 2004-06-29 2006-04-27 Novel pharmaceutical salts of 1-benzyl-4-[ (5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine ( Donepezil)
US11/557,764 US20070123565A1 (en) 2004-07-23 2006-11-08 Donepezil Hydrochloride Form VI

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2004/000227 WO2006011154A1 (en) 2004-07-28 2004-07-28 A novel polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) and a process for producing thereof

Publications (1)

Publication Number Publication Date
WO2006011154A1 true WO2006011154A1 (en) 2006-02-02

Family

ID=34959820

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2004/000227 WO2006011154A1 (en) 2003-02-12 2004-07-28 A novel polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) and a process for producing thereof

Country Status (2)

Country Link
EP (1) EP1771416A1 (en)
WO (1) WO2006011154A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111983A2 (en) * 2005-04-21 2006-10-26 Jubilant Organosys Limited NOVEL POLYMORPHIC FORM OF (l-BENZYL-4-[(5,6-DIMETHOXY-l- INDANONE)-2-YL]METHYL PIPERIDINE HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046527A1 (en) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Polymorphs of donepezil hydrochloride and process for production
EP1323712A1 (en) * 2000-09-25 2003-07-02 Eisai Co., Ltd. Process for producing multiform crystal of donepezil hydrochloride
WO2004092137A1 (en) * 2003-04-16 2004-10-28 Hetero Drugs Limited Novel crystalline forms of donepezil hydrochloride

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046527A1 (en) * 1996-06-07 1997-12-11 Eisai Co., Ltd. Polymorphs of donepezil hydrochloride and process for production
EP1323712A1 (en) * 2000-09-25 2003-07-02 Eisai Co., Ltd. Process for producing multiform crystal of donepezil hydrochloride
WO2004092137A1 (en) * 2003-04-16 2004-10-28 Hetero Drugs Limited Novel crystalline forms of donepezil hydrochloride

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006111983A2 (en) * 2005-04-21 2006-10-26 Jubilant Organosys Limited NOVEL POLYMORPHIC FORM OF (l-BENZYL-4-[(5,6-DIMETHOXY-l- INDANONE)-2-YL]METHYL PIPERIDINE HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME
WO2006111983A3 (en) * 2005-04-21 2007-03-22 Jubilant Organosys Ltd NOVEL POLYMORPHIC FORM OF (l-BENZYL-4-[(5,6-DIMETHOXY-l- INDANONE)-2-YL]METHYL PIPERIDINE HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME

Also Published As

Publication number Publication date
EP1771416A1 (en) 2007-04-11

Similar Documents

Publication Publication Date Title
US7186842B2 (en) Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof
EP1048653B1 (en) Donepezil polycrystals and process for producing the same
EP1799644B1 (en) Lercanidipine salts
CA2549752C (en) 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine oxalate (donepezil oxalate) and its polymorphs
EP1019374A1 (en) Polymorphs of donepezil hydrochloride and process for production
SK8872002A3 (en) Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and methods of using them
WO2012081031A1 (en) Process for preparing tetrabenazine
US20050288330A1 (en) Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride)
EP3295941B1 (en) Process for preparing form a of grapiprant
AU2001265377B2 (en) Crystal modification of fexofenadine
AU2001265377A1 (en) Crystal modification of fexofenadine
US20070123565A1 (en) Donepezil Hydrochloride Form VI
WO2006011154A1 (en) A novel polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) and a process for producing thereof
EP2189461B1 (en) Crystalline irinotecan hydrochloride and methods for the preparation thereof
CZ2004416A3 (en) Novel anhydrous crystalline forms of gabapentin
WO2017167949A1 (en) Crystalline forms of bilastine
WO2004099142A1 (en) Hydrobromide salt of benzyl-piperidylmethyl-indanone and its polymorphs
EP2072510A1 (en) Crystalline form of azelastine
WO2006111983A2 (en) NOVEL POLYMORPHIC FORM OF (l-BENZYL-4-[(5,6-DIMETHOXY-l- INDANONE)-2-YL]METHYL PIPERIDINE HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME
EP2154137A1 (en) Crystalline form of moxifloxacin base
AU2002330220A1 (en) New anhydrous crystalline forms of gabapentin
KR20110138040A (en) Crystalline form of donepezil base and process for preparing the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11145202

Country of ref document: US

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 197/MUMNP/2006

Country of ref document: IN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004806738

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007107364

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004806738

Country of ref document: EP